drugset / Trial / NCT02965443
Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To perform a study that investigates the effectiveness of adding the SGLT2 inhibitor dapagliflozin + the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin vs placebo to revert from a BBIT regimen to a BOT regimen in patients with type 2 diabetes.
Timeline
- Start
- 2018-02-02
- Primary completion
- 2020-02-03
- Completion
- 2020-02-03
Outcome
Outcome not reported
Stopped (Enrollment): “Low patient recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | SAXAGLIPTIN ANHYDROUS | Small molecule | 5 mg | — |